Washington, D.C. 20549






Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported):  December 5, 2016


Brainstorm Cell Therapeutics Inc.

(Exact name of registrant as specified in its charter)


Delaware   001-36641   20-7273918
(State or other jurisdiction of incorporation)   (Commission File No.)   (IRS Employer Identification No.)


3 University Plaza Drive, Suite 320    
Hackensack, NJ   07601
(Address of principal executive offices)   (Zip Code)


(201) 488-0460

(Registrant’s telephone number, including area code)



(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))





Item 7.01Regulation FD Disclosure.


On December 9, 2016, at 3:05 p.m. Greenwich Mean Time, James D. Berry, MD, MPH of the Department of Neurology at Massachusetts General Hospital, will present clinical data from Brainstorm Cell Therapeutics Inc.’s (the “Company”) NurOwn® Phase 2 Trial, at the 27th International Symposium on ALS/MND. Notice of this event was previously given on December 5, 2016 via press release, a copy of which is furnished as Exhibit 99.1 to this Form 8-K. 


The slides that will be used for the presentation will be posted on the Company’s website (www.brainstorm-cell.com) prior to the conference call. A copy of the slides is furnished as Exhibit 99.2 to this Current Report on Form 8-K.


This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.



Item 9.01Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Description
99.1   Press Release dated December 5, 2016
99.2   Presentation slides dated December 9, 2016







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: December 9, 2016 Brainstorm Cell Therapeutics Inc.  
  By: /s/ Chaim Lebovits  
  Chaim Lebovits
Chief Executive Officer and President